NCT03603002 — Sidney Kimmel Comprehensive Cancer Center… cancer immunotherapy trial
Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer
Registry record
| Registry ID | NCT03603002 ↗ |
|---|---|
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Collaborators | — |
| Phase | Phase NA |
| Status | Completed |
| Indication | Non-small Cell Lung Cancer Stage I |
| Enrollment | 6 participants |
| Start date | 2018-10-16 |
| Primary completion | 2021-09-01 |
| Last registry update | 2 Jul 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT03603002), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT03603002?
NCT03603002 (Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer) is registered on ClinicalTrials.gov as Phase NA, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Is NCT03603002 recruiting?
As of the 2026-07-02 registry update, NCT03603002 is listed as "Completed". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT03603002?
The lead sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
What condition does NCT03603002 study?
The registered condition is Non-small Cell Lung Cancer Stage I. Primary completion is listed as 2021-09-01.
Are results available for NCT03603002?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT03603002.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.